The Conversation (0)
Biogen Idec Canada (NASDAQ:BIIB) announced that its drug TECFIDERA™ which is designed for the oral treatment of multiple sclerosis has been approved by Health Canada.
Biogen Idec Canada (NASDAQ:BIIB) announced that its drug TECFIDERA™ which is designed for the oral treatment of multiple sclerosis has been approved by Health Canada.
As quoted in the press release:
TECFIDERA is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.
Click here to read the full Biogen Idec Canada (NASDAQ:BIIB) press release.